register free | resend password

Biotech

Themenbereich / / Biotech


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Functional Technologies Announces Third Quarter 2011 Financial Results

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 07/29/11 -- Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") today reported operational and financial results for the third quarter ended May 31, 2011. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP").Mr. Garth Greenham, Functional Technologies' President and COO, said, "We are pleased with the significant achievements accomplished in recent months, which demonstrates our focus in driving ...

29.07.2011

OctoPlus Announces 2011 First Half-Year Results

LEIDEN, NETHERLANDS -- (Marketwire) -- 07/29/11 -- OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the specialty pharmaceutical company, announces today its results for the six-month period ended 30 June 2011.Full development of our newly signed agreement with ESBATech, a subsidiary of Alcon/Novartis has started. This is our first project in ophthalmology (eye care). Injections into the eye are an area where the benefits of reduced injection frequency are obvious.We signed a new drug delivery evaluation contract with a top-10 biopharmaceutical company in Apri ...

29.07.2011

The Medicines Company Appoints Glenn P. Sblendorio to Board of Directors

PARSIPPANY, NJ -- (Marketwire) -- 07/28/11 -- The Medicines Company (NASDAQ: MDCO) today announced the appointment of Glenn Sblendorio to the Company's Board of Directors. Mr. Sblendorio has been Chief Financial Officer and Executive Vice President of The Medicines Company since 2006."Glenn has been a valued member of our leadership team and as a Director, I am confident he will bring the same strategic thinking and global vision to the Board as he has brought to the business over the last five years. Our focus continues to be delivering leading hospital medicines to the marketplac ...

28.07.2011

ISTA Pharmaceuticals Reports Second Quarter 2011 Financial Results

IRVINE, CA -- (Marketwire) -- 07/28/11 -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today reported financial results and progress on key milestones for the quarter ended June 30, 2011.Second Quarter 2011 HighlightsSecond quarter 2011 net revenues were $37.1 million, an increase of 6% over the second quarter of 2010.Revenues for ISTA's ophthalmic solution for ocular itching associated with allergic conjunctivitis, BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, almost doubled over the prior-year quarter, growing from $6.2 million to $12.2 million.In April 2011, ISTA announced ...

28.07.2011

Cytokinetics, Incorporated Reports Second Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/28/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development revenues of $1.1 million for the second quarter of 2011. The net loss allocable to common stockholders for the second quarter was $16.5 million, or $0.23 per basic and diluted share, which includes a one-time, non-cash dividend of $2.9 million related to the beneficial conversion feature of the Series A Convertible Preferred Stock. This is compared to a net loss of $13.1 million, or $0.21 per basic and diluted share, for the same period in 2010. As of June ...

28.07.2011

ISTA Pharmaceuticals Reports Results From the First of Two Trials in the REMURA(TM) Phase 3 Clinical Program for Dry Eye Disease

IRVINE, CA -- (Marketwire) -- 07/28/11 -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced top-line results from the first of its two Phase 3 studies to evaluate the short-term safety and efficacy of two concentrations of REMURA™ (bromfenac ophthalmic solution for dry eye) in alleviating the signs and symptoms of dry eye disease. The company's Phase 3 safety and efficacy program, which consists of two studies known as EAST and WEST, is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA). Today's top-line r ...

28.07.2011

AMI Research Updates Analyst Coverage on NeoGenomics; Maintains Outlook

NEW YORK, NY -- (Marketwire) -- 07/28/11 -- AMI Research, () a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has published updated equity research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its .AMI president Peter J. D'Agostino said, "NeoGenomics reported robust results. The company's performance and positive EBITDA has reinforced our outlook. We attribute the strong quarter to NGNM's newly restructured sales force, which has gained traction and we continue to expect NGNM to return to quarte ...

28.07.2011

Horizon Pharma Announces Pricing of Its Initial Public Offering

NORTHBROOK, IL -- (Marketwire) -- 07/28/11 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 per share. Horizon's common stock is scheduled to begin trading on The NASDAQ Global Market on July 28, 2011 under the symbol "HZNP." Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments, if any.Stifel Nicolaus Weisel, Cowen and Company and JMP Securities LLC ...

28.07.2011

Critical Outcome Technologies Inc. Initiates Synthesis of Another Key Asset: Acute Myelogenous Leukemia Drug Candidates

LONDON, ONTARIO -- (Marketwire) -- 07/28/11 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that it has initiated synthesis on compounds from COTI's acute myelogenous leukemia (AML) program, representing a positive step forward in the development of these promising new drug candidates."We are delighted to announce an important milestone in the development of our AML program," said Dr. Wayne Danter, CEO. "The synthesis of our third major drug discovery program represents further validation of CHEMSAS® as a drug discovery engine and will prov ...

28.07.2011

Bio-Solutions Corp Signs First American Distribution Agreement to Enter $45 Billion USA Poultry Market

MONTREAL, CANADA -- (Marketwire) -- 07/27/11 -- Bio-Solutions Corp (OTCBB: BISU)(PINK SHEETS: BISU) is proud to announce that it has signed a distribution agreement with it's first American distributor, Faunus Global, for sales and distribution of it's NutraAnimal™. NutraAnimal™ is an organic alternative livestock feed, composed of aquatic milled marine source."I am very happy to have this opportunity to work with Bio-Solutions as their first American distributor", said Mr. Douglas Schapero, Member of Faunus Global. "The American poultry market is the largest in the ...

27.07.2011

Two Patent Grants Add to Stem Cell Therapeutics Corp. Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Technologies

CALGARY, ALBERTA -- (Marketwire) -- 07/27/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce that it has received notification of the issuance of two additional patents. The first entitled "Use of Luteinizing Hormone (LH) and Chorionic Gonadotropin (hCG) for Proliferation of Neural Stem Cells and Neurogenesis" and was granted by the Australian Patent office; Patent number 2005211847. The second is entitled "Production of Radial Glial Cells" and was issued by the Canadian Intellectual Property Office; P ...

27.07.2011


Page 247 from 247:  « ..  243  244  245  246 247





All members: 9 375
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 53


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.